These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34108247)

  • 1. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression.
    Nagele P; Palanca BJ; Gott B; Brown F; Barnes L; Nguyen T; Xiong W; Salloum NC; Espejo GD; Lessov-Schlaggar CN; Jain N; Cheng WWL; Komen H; Yee B; Bolzenius JD; Janski A; Gibbons R; Zorumski CF; Conway CR
    Sci Transl Med; 2021 Jun; 13(597):. PubMed ID: 34108247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.
    Nagele P; Duma A; Kopec M; Gebara MA; Parsoei A; Walker M; Janski A; Panagopoulos VN; Cristancho P; Miller JP; Zorumski CF; Conway CR
    Biol Psychiatry; 2015 Jul; 78(1):10-18. PubMed ID: 25577164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial.
    Yan D; Liu B; Wei X; Ou W; Liao M; Ji S; Peng Y; Liu J; Wu S; Wang M; Ju Y; Zhang L; Li Z; Li L; Zhang Y
    Psychiatry Res; 2022 Nov; 317():114867. PubMed ID: 36191556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression:Evidence from task-state EEG.
    Shao X; Yan D; Kong W; Sun S; Liao M; Ou W; Zhang Y; Zheng F; Li X; Li L; Hu B
    Psychiatry Res; 2023 Apr; 322():115072. PubMed ID: 36791487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement.
    Kim WSH; Dimick MK; Omrin D; Mitchell RHB; Riegert D; Levitt A; Schaffer A; Belo S; Iazzetta J; Detzler G; Choi M; Choi S; Herrmann N; McIntyre RS; MacIntosh BJ; Orser BA; Goldstein BI
    Bipolar Disord; 2023 May; 25(3):221-232. PubMed ID: 36579458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical evidence for the neurocognitive effect of nitrous oxide as an adjunctive therapy in patients with treatment resistant depression: A randomized controlled study.
    Liu J; Zhao X; Wei X; Yan D; Ou W; Liao M; Ji S; Peng Y; Wu S; Wang M; Ju Y; Zhang L; Li Z; Liu B; Li L; Zhang Y
    Psychiatry Res; 2023 Aug; 326():115326. PubMed ID: 37390601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial.
    Guimarães MC; Guimarães TM; Hallak JE; Abrão J; Machado-de-Sousa JP
    Braz J Psychiatry; 2021; 43(5):484-493. PubMed ID: 33605397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Mood Improvement with Laughing Gas Exposure (SMILE): Study protocol for a randomized placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression.
    Ladha KS; Lee J; Mattina GF; Pazmino-Canizares J; Wijeysundera DN; Gholamali Nezhad F; Philip K; Tassone VK; Adamsahib F; Bhat V;
    PLoS One; 2024; 19(1):e0297330. PubMed ID: 38241247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders.
    Rech P; Custodio RM; Rodrigues Uggioni ML; Silveira Prestes G; Marçal F; Silveira VP; Dagostin VS; Colonetti T; Rosa MI
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110869. PubMed ID: 37813146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Nitrous Oxide as a Treatment for Subjective, Idiopathic, Nonpulsatile Bothersome Tinnitus: A Randomized Clinical Trial.
    Hong HY; Karadaghy O; Kallogjeri D; Brown FT; Yee B; Piccirillo JF; Nagele P
    JAMA Otolaryngol Head Neck Surg; 2018 Sep; 144(9):781-787. PubMed ID: 30073285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of SAGE-217 in Patients with Major Depressive Disorder.
    Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
    N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
    Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
    Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
    Quach DF; de Leon VC; Conway CR
    J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
    J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.